Trials / Recruiting
RecruitingNCT07292688
Study of CM383 in Healthy Subjects
A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CM383 Following Intravenous and Subcutaneous Administration in Healthy Adult Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383 administered via intravenous infusion or subcutaneous injection in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM383 | CM383 subcutaneous injection, once. |
| BIOLOGICAL | CM383 | CM383 intravenous infusion, once. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2025-12-18
- Last updated
- 2026-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07292688. Inclusion in this directory is not an endorsement.